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Background/aim: One of the functions of fetuin-A is the restriction of formation and expansion of extraosseous hydroxyapatite crystals.
The exact correlation of fetuin-A with bone mineral density (BMD) has not been clearly elucidated yet. In this study, we aimed to assess
the relationship between BMD and fetuin-A in postmenopausal women.
Materials and methods: Fifty postmenopausal women (25 with osteoporosis, 25 healthy controls) were included in the study. All
participants were comparable for age and body mass index. None of the osteoporotic patients had received any medical treatment for
osteoporosis. Serum fetuin-A levels were measured by ELISA method.
Results: BMD scores of the groups were statistically significant (P < 0.001). Serum fetuin-A levels of the osteoporosis group were
significantly lower compared to the control group (P = 0.009). Additionally, there was there was a mild to moderate positive correlation
between fetuin-A and lumbar (r = 0.381, P = 0.06) and femoral (r = 0.143, P = 0.50) BMD in the osteoporotic group, though it did not
reach statistical significance.
Conclusion: Decreased fetuin-A levels in women with postmenopausal osteoporosis suggest that fetuin-A may have a role in the
development of osteoporosis. Further studies are required to define the exact role of fetuin-A in bone metabolism.
Key words: Fetuin-A, bone mineral density, osteoporosis

1. Introduction
Osteoporosis prevalence is consistently increasing due
to increased life expectancy worldwide. It is known that
one of the most common causes of hospitalization among
elderly people, and especially postmenopausal women, is
hip fractures due to osteoporosis (1–3). Nearly half of all
women are expected to suffer an osteoporotic fracture in
their lifetime (4). Twenty percent of the patients with hip
fracture become functionally dependent and require longterm nursing care (5). Additionally, postfracture mortality
rate is as high as 20% within the first year (6). Thus, most
relevant studies are aimed at developing new treatment
modalities to alleviate the burden of this health problem.
Although it is well known that the age and female sex are
strong risk factors for osteoporosis, biological pathways
possibly leading to osteoporosis are still unclear. Discovery
of these pathways effective in osteoporosis may lead to
* Correspondence: ozkanesin@yahoo.com

development of new preventive or therapeutic strategies in
the management of these patients (7).
Fetuin-A (α2-Heremans–Schmid glycoprotein) is a
glycoprotein that is expressed not only from the liver, but
also from the kidney and choroid plexus. Normal serum
concentrations of fetuin-A in healthy adults range between
0.5 and 1.0 g/L. Fetuin-A is highly expressed in the noncollagenous bone matrix during fetal life and affects bone
growth via antagonizing the effects of transforming growth
factor beta (8–10). Lack of fetuin-A has been shown to result in severe systemic calcification in mice and humans
(11,12). Fetuin-A facilitates the removal of hydroxyapatite crystals by increasing the calciprotein particles in the
bloodstream and, therefore, inhibiting intravascular calcification (9).
The exact mechanism of fetuin-A on bone
mineralization has not been completely elucidated.
During their in vitro rat study, Toroian et al. noted that
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fetuin-A stimulated calcification within bone (13). There
are limited human studies on fetuin-A to define its exact
mechanism (7,14). In this study, we aimed to evaluate the
correlation of fetuin-A levels and bone mineral density
(BMD) in a group of 50 postmenopausal women.
2. Materials and methods
Twenty-five postmenopausal women with osteoporosis
and 25 age- and body mass index (BMI)-matched healthy
postmenopausal women were included in the study (Table).
All participants provided written informed consent. The
study protocol was approved by the local ethics committee
of Gülhane Military Medical Academy.
Patients with vertebral fractures, surgical menopause,
secondary osteoporosis, or other medical conditions
that may affect the skeletal tissue or metabolism were
excluded from the study. Patients previously treated with
bisphosphonates, calcitonin, and anabolic steroids or who
received hormone replacement therapy at any time after
menopause were also excluded.
The diagnosis of osteoporosis was established by
lumbar spinal and femoral BMD measurements were
made using dual-energy X-ray absorptiometry (DXA;
QDR-4500, Hologic, Bedford, MA, USA) according to
World Health Organization diagnostic criteria (15).
Fetuin-A was measured in duplicate using an ELISA
kit (BioVendor Laboratory Medicine GmbH, Heidelberg,
Germany) following the instructions of the manufacturer.
Coefficients of intraassay and interassay variations of
serum fetuin-A levels were found to be 3.0% and 5.4%,
respectively. Venous blood samples were collected after
a 12-h fasting period into tubes containing clot activator
to obtain serum. The tubes were allowed to clot before
centrifugation. All tubes were then centrifuged at 2000

× g for 10 min. All sera were stored at –80 °C until final
analysis.
Statistical analyses were performed using SPSS 11.5 for
Windows (SPSS Inc., Chicago, IL, USA). Normality tests
were performed by one-sample Kolmogorov–Smirnov
test. Appropriate statistical tests were then selected.
Mean values were compared using Student t-tests and
correlations were analyzed by using Pearson and Spearman
rank coefficients. Statistical significance was set at P < 0.05.
3. Results
Patient characteristics are presented in the Table.
Demographical characteristics of the 2 groups were similar,
including age and BMI. Serum fetuin-A levels were found
to be significantly lower in the osteoporotic group (0.82 ±
0.14 mg/L) than in the control group (0.93 ± 0.12 mg/L) (P
= 0.009). Although there was a mild to moderate positive
correlation between fetuin-A levels and lumbar (r = 0.381,
P = 0.06) and femoral (r = 0.143, P = 0.50) BMD in the
osteoporotic group, it did not reach statistical significance.
There was no statistically significant correlation of BMI or
serum Ca levels with fetuin-A. Additionally, correlation
coefficients between fetuin-A and lumbar and femoral
BMD in the osteoporotic group were r = 0.381, P = 0.06
and r = 0.143, P = 0.50, respectively.
4. Discussion
Recent clinical studies have shown that fetuin-A plays a role
in the regulation of bone homeostasis and stimulates bone
mineralization (10,16,17). However, the exact mechanism
of action and its effects are still uncertain. There are
limited studies about the relationship between fetuin-A
and osteoporosis BMD levels (7,14). Our hypothesis in

Table. Demographic and clinical characteristics of the postmenopausal osteoporotic women in the
study group and the control group.
Parameters

Control group
(n = 25)

Osteoporosis group
(n = 25)

P-value

Age (years)

62.48 ± 7.44

65.88 ± 7.26

0.11

BMI (kg/m2)

28.62 ± 3.00

27.34 ± 2.76

0.13

Serum total Ca (mg/dL)

9.60 ± 0.50

9.59 ± 0.44

0.95

Lumbar BMD (DXA)

1.01 ± 0.13

0.72 ± 0.06

<0.001

F. neck BMD (DXA)

0.82 ± 0.09

0.65 ± 0.07

<0.001

F. total BMD (DXA)

0.92 ± 0.13

0.75 ± 0.14

<0.001

Fetuin-A (ng/mL)

0.93 ± 0.12

0.83 ± 0.14

0.009

All data are reported as mean ± SD.
Ca: Calcium; F: femoral; BMI: body mass index; BMD: bone mineral density.
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this study was that elderly osteoporotic women with lower
BMD results will show lower fetuin-A levels.
In 2002, Szweras et al. (18) examined bone growth and
remodeling in fetuin-A deficient mice. They found that
fetuin-A–deficient mice seemed to be skeletally normal
at birth, but growth retardation was observed between
3 and 18 months of age due to deficient maturation of
the chondrocytes in the growth plate. Cortical thickness,
trabecular bone remodeling, number of osteoblasts, and
bone formation were also found to be increased in the same
study. In our study, fetuin-A levels were found to be lower in
osteoporotic elderly women with low BMD values.
In their study in 2008, Toroian and Price (17)
demonstrated that mineral formed only within collagen
fibrils when fetuin was present, but mineral formed only
in solution outside the fibrils when fetuin was absent.
They suggested that fetuin-A may be selectively inhibiting
crystal formation outside the fibril and thus promoting
fibril mineralization. Fetuin-A has also been reported to
correlate with bone turnover markers (16).
The first study in the literature that analyzed the
association between fetuin-A and BMD was done by Ix

et al. (7). They analyzed the serum fetuin-A levels of 580
people in a group of 3075 well-functioning black and
white persons (70–79 years) whose BMD values were
already known. They found that higher fetuin-A levels
were correlated with higher BMD values in older women
but not in men. In another clinical study, fetuin-A levels
were found to be positively correlated with lumbar, but
not femoral, BMD values (14). According to our results,
osteoporotic women had significantly lower fetuin-A
levels than normal control subjects and, similar to the
previously mentioned study, fetuin-A levels correlated
more with lumbar BMD values than femoral values.
Although we determined a statistically significant
difference of fetuin-A level between osteoporotic and
healthy people, we could not show dose-response
association by correlations.
In conclusion, our preliminary findings suggest that
serum fetuin-A might be related to osteoporosis and it
may provide necessary information on the pathogenesis.
Further studies with larger samples are required to define
the exact role of fetuin-A in bone metabolism and its
possible reflections on osteoporotic fractures.
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